Cara Therapeutics | CARA - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Alterity Therapeutics Limited AUD 10.88B 10.66B 2025-12
Cara Therapeutics USD 9.38M 2.01K 2026-03
Cassava Sciences USD 48.31M 0 2026-03
Chugai Pharma JPY 1.65B 460K 2026-06
Cipla INR 807.78M 17K 2026-03
Clal Biotechnology ILS 1.61M 0 2022-12
Compugen USD 94.55M 1000 2026-03
CSL USD 482.13M 93.87M 2025-12
Grifols EUR 680.58M 846.11K 2025-12
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
J&J USD 2.41B 1.35M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Pacira USD 39.82M 512K 2026-06
Pfizer USD 5.7B 0 2026-06
RedHill Biopharma USD 50.92B 17.62B 2025-12
Supernus Pharmaceuticals USD 58.16M 124K 2026-06
Vanda Pharmaceuticals USD 58K 0 2024-12